Johnson & Johnson may pay cancer patient $110M over baby powder

A 62-year-old woman diagnosed with ovarian cancer could receive $110 million dollars from health products giant Johnson & Johnson after alleging the company didn’t disclose the cancer risk of its baby powder and other products.

Lois Slemp was diagnosed with ovarian cancer in 2012 and was quick to blame Johnson & Johnson, claiming the company would have known about the talc in its baby powder and Shower to Shower products.

This is not the first major lawsuit the company has faced regarding talc in its products. The company lost $72 million in one case, $70 million in another case, and $55 million in a third case. Securities and Exchange Commission said the company also faces multiple federal class-action suits.

The jury in Slemp’s case sided with Slemp.

“They chose to put profits over people, spending millions in efforts to manipulate scientific and regulatory scrutiny,” said Ted Meadows, a Beasley Allen lawyer representing Slemp and other similar plaintiffs. “I hope this verdict prompts J&J to acknowledge the facts and [helps] educate the medical community and the public about the proper use of their products.”

USA Today reports Johnson & Johnson continues to deny the connection between talc and cancer, saying, “We deeply sympathize” with anyone affected by ovarian cancer. The manufacturer said it would appeal the verdict, citing several other recent cases won that “highlight the lack of credible scientific evidence behind plaintiffs’ allegations.”

If you would like to receive Breaking News text alerts on a smartphone or tablet, download the DML APP which is completely FREE and easy to use. Go to the Google Play Store or the IOS App Store and search for DML APP. Be sure to keep the app’s notifications setting on. Another way to receive alerts is to text to 40404 the following message: follow @realdennislynch (be sure to put a space between the word follow and the @ symbol).

To see more stories like this, sign up below for Dennis Michael Lynch’s email newsletter.







 

Comment via Facebook

Send this to a friend